ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers
Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class ...